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INTRODUCTION
Kawasaki disease, first described by Kawasaki in 1967, is
an acute febrile illness of early characterized by prolonged
fever, polymorphous skin rash, conjunctival injection, oral
mucosal changes, erythematous induration of hands and feet,
and cervical lymphadenopathy (1). Although the clinical and
epidemiological features suggest an infectious origin, its eti-
ology remains unknown. In the acute stages, it can be very
difficult to differentiate it from other febrile infectious dis-
eases. Especially, Kawasaki disease shares some clinical find-
ings with measles such as high fever, conjunctivitis, skin rash,
and so forth. It is important to differentiate of these diseases
in the acute febrile stage in measles endemic areas.
Numerous studies have demonstrated the interaction be-
tween leukocytes and vascular endothelial cells likely con-
tributes to the pathogenesis of Kawasaki disease, and vascu-
lar lesions are infiltrated by large numbers of mononuclear
cells in response to chemotactic stimuli (2-4).
Recently, Wong and associates (5) have been concerned
about chemokines (6), a newly identified family of proinflam-
matory cytokines in Kawasaki disease. So it is important to
understand the factors that may recruit and activate leuko-
cytes to the regions of vasculitis in this disease (7-16). How-
ever, comparing the profiles of these chemokines between
Kawasaki disease and measles have not been studied yet. 
In the present study, we compared the production and gene
expressions of chemokine; Gro- (growth-related oncogene- )
and RANTES (regulated upon activation in normal T cells
expressed and secreted) in peripheral blood from patients with
Kawasaki disease and measles.
MATERIALS AND METHODS
Study population 
The study cohort were composed of three groups. The first
group included 14 consecutive patients (10 males, 4 females;
mean age, 35.6 months, range 11 to 83 months) who met the
diagnostic criteria for Kawasaki disease as described elsewhere
(1). All patients received high dose single intravenous gamma
globulin (IVIG) infusion (Liv-gamma 2 g/kg in 10 to 12
hr) in combination with oral aspirin (Rhonal 60-100 mg/kg
divided into 3 equal doses) treatment within the first 10 days
of illness (acute phase) and were prospectively evaluated at
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We investigated whether the production and gene expression of Gro- and
RANTES in Kawasaki disease differ in measles. Forty-two samples from 14 patients
in different clinical stages of Kawasaki disease, eight samples from 8 patients in
the acute stage of measles and seven samples from 7 healthy children were col-
lected. The present study was performed using ELISA and RT-PCR for the pro-
ductions and gene expression of the chemokines. The production of Gro- was
markedly elevated during the acute stage of measles compared with Kawasaki
disease. Moreover, the expression of Gro- was increased in every case of me-
asles, but not in Kawasaki disease. The production of RANTES was elevated in
the acute stage of both diseases when compared to the healthy control. However,
the plasma RANTES level did not change significantly according to the clinical
stages of Kawasaki disease. A correlation between the production and gene expres-
sion of RANTES and Gro- was not found in Kawasaki disease. These results sug-
gest that Kawasaki disease differs from measles with regard to Gro- production
and expression, but not RANTES. Gro- might play an important role in the acute
stage of measles, however not in Kawasaki disease. Further studies are needed
to clarify the efficacy of Gro- as a marker in measles.
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Yeungnam University Hospital, Dae-Gu, Korea. All patients
underwent serial blood sampling and echocardiographic eval-
uation. The blood sampling and echocardiographic study was
done according to the disease course as follows; acute stage,
before treatment with IVIG and aspirin, subacute stage, 7 to
10 days after intravenous gamma globulin treatment, and
convalescent stage, 30 to 40 days after the onset of the Kawa-
saki disease. Normal ranges for coronary artery size defined
according to diagnostic criteria of the Research Committee
on Kawasaki disease, Ministry of Health and Welfare, Japan
(17). In younger than 5 yr, internal lumen diameters of 3 mm
or more, and in aged 5 yr or older, internal lumen diameter
of 4 mm or more is considered coronary artery dilatation. Three
patients were found to have dilatations of the coronary arter-
ies. In all of them, the echocardiographic findings became nor-
mal during one year of follow-up. None of the patients died.
The second group included 8 samples from eight patients
(3 males, 5 females; mean age, 28.1 months, ranges from 7
to 128 months) in the acute febrile stage of measles. And 7
healthy children (4 males, 3 females; mean age, 34.3 months,
ranges from 8 to 55 months) who had no apparent underly-
ing diseases composed the third group (Table 1).
Informed consents were obtained from the parents of the
patients included in this study.
Echocardiographic assessment of coronary artery
The 2-dimensional echocardiographic study was performed
with a 7.5 MHz transducer (Sequoia CA, U.S.A.) to obtain
the coronary artery dimension at the level of the aortic root in
the parasternal short axis view. All patients received a single
dose of chloral hydrate (80 mg/kg) orally for sedation. 
Sera
Samples of venous blood were obtained from patients and
controls, and were centrifuged at 2,000 rpm/min for 30 min.
After the isolation of peripheral blood mononuclear cells
(PBMCs), serum samples were frozen at -70 for the ELISA
assay. 
Reagents
Reverse transcriptase-polymerase chain reaction (RT-PCR)
kits were purchased from Perkin-Elmer (Norwalk, CT, U.S.A.).
Trizol solution for total RNA isolation and a 100 bp DNA
ladder as molecular weight marker were obtained from Gibco/
BRL (Life Technologies, Gaithersburg, MD, U.S.A.).
ELISA assay 
ELISAs for RANTES and Gro- were performed accord-
ing to manufacturer' s instruction using kits from R&D sys-
tems (Minneapolis, MN, U.S.A.). Briefly, add 100  L of stan-
dards or patient serum was incubated in anti-human RANTES
(or Gro- ) coated well plates at room temperature for 2 hr.
After the 200  L of prepared biotinylated antibody was added,
the plates were incubated at room temperature for 1 hr, and
then the 200  L of tetramethylbenzidine substrate solution
was added and the plates were developed in the dark state at
room temperature for 20 min. The reaction was ceased by
adding 50  L of stop solution. Absorbence of serum was mea-
sured at 450 nm for RANTES and Gro- .
PBMCs isolation and total RNA isolation 
PBMC were isolated by density centrifugation on a Ficoll-
Hypaque gradient at 2,000 rpm for 30 min, then total RNA
was isolated with the use of Trizol solution, as instructed by
the manufacturer. Briefly, after the addition of 1 mL of Trizol
and 200  L of chloroform followed by centrifugation, the aq-
ueous phase was combined with an equal volume of isopropa-
nol. The precipitated pellet was washed with 70% ethanol, and
suspended again in diethylpyrocarbonate (DEPC)-treated water.
Chemokine RT-PCR
Reverse transcription and PCR amplification were perform-
ed as described by Cha et al. (18). One  g of total RNA per
sample were reverse transcribed using Moloney murine leuk-
emia virus reverse transcriptase (Perkin Elmer, Norwalk, CT,
U.S.A.) and oligo dT priming according to the manufactur-
er' s instruction, at 42 for 15 min. Amplification with spe-
cific primers was performed in a Gene Amp PCR system 9600
(Perkin Elmer) 35 cycles for 15 sec, 95 denaturation for 30
sec, 60 annealing for 1 min, 94 denaturation for 1 min,
60 annealing for 1.5 min, 72 extension profile in case of
RANTES. Amplification of mRNA for the housekeeping gene
-actin was used as internal quality standard. Amplified prod-
ucts were electrophoresed on 1.5-2% agarose gel stained with
0.5  g/mL ethidium bromide. The primer sequences were as
follows:  -actin (712 bp) sense; 5 -cgggaaatcgtgcgtgat-3 ,
antisense; 5 -gaactttgggggatgctcgc-3 , RANTES (275 bp)
sense; 5 -atgaaggtctccgcggcacgcc-3 , antisense; 5 -ctagctc-
atctccaaagagtt-3 , Gro- (585 bp) sense; 5 -actgaactgcgct-
gccagtg-3 , antisense; 5 -ggcatgttgcaggcttcctca-3 .
Statistical Methods
Results were presented as mean SD. Statistical differ-
ences were analyzed by the Mann-Whitney test. A p-value
Cases (male/female) 14 (10/4) 8 (3/5) 7 (4/3)
Age (range, months) 35.6* (11-83) 28.1* (7-128) 34.3 (8-55)
*p>0.05.
Characteristics Kawasaki disease Measles Healthy control
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<0.05 was considered significant.
RESULTS
Plasma levels of Gro-
The plasma levels of Gro- were markedly elevated dur-
ing the acute stage of measles than those of the patients with
Kawasaki disease and healthy control group (p<0.01) (Fig. 1).
Among the patients with Kawasaki disease, it is somewhat
elevated in the subacute stage, but we could not find obvious
elevation of plasma Gro- level when compared with healthy
control group (Fig. 2).
Plasma levels of RANTES
The plasma levels of RANTES were more elevated in the
acute stage of Kawasaki disease than measles and healthy con-
trols (Fig. 3), but there was no statistical significance. Among
the patients with Kawasaki disease, there was no obvious cor-
relation between clinical stages of the Kawasaki disease and
the plasma levels of RANTES, yet it is elevated in each stage
(Fig. 4).
Expression of Gro- and RANTES mRNA in PBMCs
The expression of Gro- mRNA was increased in every case
of measles, but was not in the acute stage of the Kawasaki
disease and the control group. RANTES mRNA was ex-
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Fig. 1. The plasma levels of Gro- in the control, acute stage of the
measles and Kawasaki disease by ELISA.
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Fig. 2. The changes of plasma level of Gro- according to the clin-
ical stages of Kawasaki disease.
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Fig. 3. The acute stage plasma levels of RANTES in the measles,
Kawasaki disease and control group by ELISA.
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Fig. 4. The change of plasma levels of RANTES according to the
clinical stages of Kawasaki disease.
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pressed extensively in both diseases, but not in the control
group (Fig. 5).
According to the clinical stages in Kawasaki disease, RAN-
TES mRNA was expressed inconsistently, but Gro- mRNA
was not expressed (Fig. 6).
DISCUSSION
Kawasaki disease is an acute febrile illness of early childhood
(1). Although the clinical and epidemiological features sug-
gest an infectious origin, its etiology remains unknown. Histo-
pathological findings in Kawasaki disease indicate a vasculi-
tis that predominantly affects the medium-sized arteries (19,
20).
The differential diagnosis includes scarlet fever, toxic shock
syndrome, measles, drug reaction, viral infection, and other
vasculitis syndromes. Especially, Kawasaki disease shares some
clinical findings with measles such as high fever, conjunctivi-
tis, and skin rash. It is important to differentiate of these dis-
easesduring the acute febrile stage in endemic areas of measles.
Elevated levels of various pro-inflammatory cytokines have
been detected in the peripheral blood of patients with Kawa-
saki disease during the acute stage (2-5, 7-16). During the
acute stage of Kawasaki disease, increased production of tumor
necrosis factor  (TNF ), interleukin-1 (IL-1 ), IL-2, inter-
feron- (IFN- ), and IL-6 have been detected in the circula-
tion of patients with Kawasaki disease (7-13). TNF , IL-1 ,
and IFN- induce activation of antigens and adhesion mole-
cules, such as endothelial leukocyte adhesion molecule-1
(ELAM-1) and intercellular adhesion molecule-1 (ICAM-1),
on endothelial cells, and TNF and IFN- cause endothe-
lial injury in vitro studies (21). These four mentioned factors
may play a key role in the pathogenesis of both immune acti-
vation and endothelial cell damage, and suggested to be as
predictable factors of coronary aneurysm in Kawasaki disease
(15, 16). Wong et al. (5) reported that RANTES, monocyte
chemoattractant protein-1 (MCP-1) and Macrophage Inflam-
matory Protein-1 (MIP-1 ) gene expression levels were sig-
nificantly elevated in the peripheral blood with Kawasaki dis-
ease. Therefore, in Kawasaki disease, the presence of circulat-
ing chemokines may lead to an increased immune cell adhe-
sion to activated endothelial cells, resulting in tissue damage.
The chemokines (chemotactic cytokines) are a large family
of cytokines composed of small pro-inflammatory peptides
that regulate trafficking, activation and sometimes the pro-
liferation of myeloid, lymphoid, melanocytes, and endothe-
lial cells (22). The chemokines presently comprise approxi-
mately 60 members. Based on the predicted primary amino
acid structure, the superfamily is divided into four groups
Fig. 5. The expression of Gro- and RANTES mRNA of PBMC in the patients with the acute stage of Kawasaki disease, measles and con-
trol group, respectively, analyzed by RT-PCR. The  -actin was used as internal standard. These data are representatives of all the patients
analyzed. The expression of Gro- mRNA was consistent, but not RANTES. pt, Kawasaki disease patient; m, measles patient; c, healthy
control; PBMC, peripheral blood mononuclear cell; RT-PCR, reverse transcription-polymerase chain reaction.
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Fig. 6. The mRNA expression profiles of Gro- and RANTES during the 3 stages of Kawasaki disease. Total RNA was isolated from PBMC
collected from Kawasaki disease patients, and RT-PCR was performed with primers indicated as described in materials and methods.
Data are representatives of all patients analyzed. The  -actin was used as internal standard. Pt, patient; 1st, acute stage; 2nd, subacute
stage; 3rd, convalescent stage; PBMC, peripheral blood mononuclear cell; RT-PCR, reverse transcription-polymerase chain reaction.
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(23-25): the CXC or  chemokines, the CC or  chemokines,
the C or  chemokines, and the CX3C or  chemokines. 
The chemokine Gro- is a member of the CXC chemokine
and is chemotactic for neutrophils, basophils, monocytes, and
lymphocytes, and is responsible for much of the tissue dam-
ages associated with chronic infection. Gro- is over expressed,
contribute to the ongoing inflammatory process and neutro-
phil infiltration associated with various diseases including
psoriasis (26, 27), rheumatoid arthritis (28), and ulcerative col-
itis (29). And also, it is angiogenic (30), like IL-8, and has a
role in wound healing (31, 32) through the stimulation of the
proliferation of keratinocytes. It is also speculated, although not
yet proven, Gro- performs the function of IL-8 in mice (6). 
Recent study reports that IL-8 and RANTES have been
suggested to be involved in the pathogenesis of Kawasaki
disease (5, 33). Moreover, RANTES mRNA was induced
by measles virus infection (34). So we focused on RANTES
and Gro- instead of IL-8.
In this study, the production of Gro- was markedly ele-
vated during the acute stage of measles than Kawasaki disease
and healthy control. And there were no remarkable changes
of plasma level of Gro- according to the clinical stages in
Kawasaki disease (levels were below 150 pg/mL). This was
coincided with the expression patterns of Gro- mRNA. The
expression of Gro- mRNA was increased in every case of
measles, but not in Kawasaki disease, even in different clin-
ical stages. Therefore, the production and gene expressions of
Gro- seem to have no significant correlation on the clinical
stages of Kawasaki disease. Otherwise, we assume that Gro-
might play an important role in the acute febrile stage of me-
asles.
The chemokine RANTES belongs to the CC chemokines
and attract mainly T lymphocytes and monocytes, and is in-
volved in a number of inflammatory diseases, including rheu-
matoid arthritis (35), allergy in airway (36), and multiple scle-
rosis (37).
The production of RANTES was elevated in the acute stage
of Kawasaki disease and measles than healthy control in this
study. However, there were no significant changes of plasma
RANTES levels according to the clinical stages of Kawasaki
disease. The mRNA of RANTES was expressed, but was not
consistent according to the clinical stages. We presume that
would be the natural course of Kawasaki disease or one of the
effects of the IVIG infusion. So we could not find any obvi-
ous correlation between the plasma level and gene expression
of RANTES in the patients with Kawasaki disease. 
And also, there was no obvious relation between clinical
characteristics of the disease including the coronary artery
dilatation and RANTES. These results were similar to Wong
et al. (5), demonstrating that RANTES gene expression lev-
els were significantly elevated, but there was no obvious cor-
relation between the clinical stage of Kawasaki disease and
chemokine expression level. Otherwise, they reported that
persistence or increased expression of RANTES gene into
convalescent stage may contribute to further risk of coronary
artery dilatation. In the acute stage of measles, the expression
of RANTES mRNA was strong that was similar to Noe et
al. (34). The expression patterns of chemokine genes are
variable according to the studies (37-40). Further study for
the chemokine expressions and roles are still required in
Kawasaki disease and measles.
In conclusion, these results suggested that Kawasaki disease
differs from measles with regard to Gro- production and
expression, but not RANTES. Gro- might play an impor-
tant role in the acute febrile stage of measles, but not in Kawa-
saki disease. Further studies are needed to clarify the efficacy
of Gro- as a marker for activities of measles.
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